{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:07:57Z","timestamp":1782385677114,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is increasingly recognized as a multifactorial disorder with vascular contributions, including a pro-coagulant state marked by fibrin deposition in the brain. Fibrin accumulation may exacerbate cerebral hypoperfusion and neuroinflammation, leading to neurodegeneration. Identifying patients with this pathology could enable targeted anticoagulant therapy. However, current imaging tools lack the specificity and sensitivity to detect fibrin in the brain non-invasively. This study aimed to develop and evaluate brain-penetrating peptide- and antibody-based PET radioligands targeting fibrin to enable individualized treatment strategies in AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A fibrin-binding peptide (FBP) was conjugated to the antibody fragment scFv8D3, which targets the transferrin receptor (TfR), to facilitate transcytosis across the blood-brain barrier. FBP-scFv8D3 bound TfR and with modest affinity to fibrin. In vivo studies in Tg-ArcSwe mice, that exhibit fibrin along with brain amyloid-\u03b2 pathology, and wild-type mice showed that [\n                      <jats:sup>125<\/jats:sup>\n                      I]FBP-scFv8D3 retained brain-penetrating properties but did not demonstrate significant fibrin-specific retention. In contrast, the monoclonal antibody 1101 and its bispecific, brain penetrant variant 1101-scFv8D3 exhibited higher fibrin selectivity and TfR binding. Both antibodies showed a trend towards higher brain retention in Tg-ArcSwe mice and [\n                      <jats:sup>125<\/jats:sup>\n                      I]1101-scFv8D3 showed a higher brain-to-blood ratio compared to [\n                      <jats:sup>124<\/jats:sup>\n                      I]1101. PET imaging with [\n                      <jats:sup>124<\/jats:sup>\n                      I]1101 and [\n                      <jats:sup>124<\/jats:sup>\n                      I]1101-scFv8D3 revealed low global brain uptake. However, ex vivo autoradiography and regional PET quantification (ROI-to-cerebellum ratios) indicated significant cortical and caudate retention of [\n                      <jats:sup>124<\/jats:sup>\n                      I]1101-scFv8D3 in Tg-ArcSwe mice, supporting region-specific target engagement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This proof-of-concept study demonstrates the feasibility of using bispecific antibody-based PET radioligands to target fibrin in the AD brain. While the FBP-scFv8D3 conjugate showed limited specificity, the bispecific antibody 1101-scFv8D3 exhibited higher brain penetration and fibrin selectivity. These findings support further development of antibody-based imaging tools toward the goal to stratify AD patients who may benefit from anticoagulant therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-025-00383-2","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:42:10Z","timestamp":1757346130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brain-penetrating peptide and antibody radioligands for proof-of-concept PET imaging of fibrin in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"10","author":[{"given":"Dag","family":"Sehlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cort\u00e9s-Canteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Syv\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-6962","authenticated-orcid":false,"given":"Sara","family":"Lopes van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"383_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1021\/cr0782426","volume":"108","author":"SM Ametamey","year":"2008","unstructured":"Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501\u201316.","journal-title":"Chem Rev"},{"key":"383_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06077.x","volume":"1228","author":"S Basu","year":"2011","unstructured":"Basu S, et al. Fundamentals of PET and PET\/CT imaging. Ann N Y Acad Sci. 2011;1228:1\u201318.","journal-title":"Ann N Y Acad Sci"},{"key":"383_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2967\/jnumed.115.157982","volume":"56","author":"F Blasi","year":"2015","unstructured":"Blasi F, et al. Radiation dosimetry of the fibrin-binding probe 64Cu-FBP8 and its feasibility for PET imaging of deep vein thrombosis and pulmonary embolism in rats. J Nucl Med. 2015;56:1088\u201393.","journal-title":"J Nucl Med"},{"key":"383_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40035-022-00324-y","volume":"11","author":"G Bonvicini","year":"2022","unstructured":"Bonvicini G, et al. ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer\u2019s disease with a bispecific, brain-penetrating fusion protein. Transl Neurodegener. 2022;11:55.","journal-title":"Transl Neurodegener"},{"key":"383_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/978-3-319-98947-1_25","volume-title":"Radiopharmaceutical chemistry","author":"J Cardinale","year":"2019","unstructured":"Cardinale J, Giammei C, Jouini N, Mindt TL. Bioconjugation methods for radiopharmaceutical chemistry. Radiopharmaceutical chemistry. Cham: Springer International Publishing; 2019. pp. 449\u201366. https:\/\/doi.org\/10.1007\/978-3-319-98947-1_25"},{"key":"383_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1021\/mp300610s","volume":"10","author":"KL Ciesienski","year":"2013","unstructured":"Ciesienski KL, et al. Fibrin-targeted PET probes for the detection of thrombi. Mol Pharm. 2013;10:1100\u201310.","journal-title":"Mol Pharm"},{"key":"383_CR27","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/acs.bioconjchem.6b00235","volume":"27","author":"BE Cook","year":"2016","unstructured":"Cook BE, et al. Pretargeted PET imaging using a site-specifically labeled immunoconjugate. Bioconjug Chem. 2016;27:1789\u201395.","journal-title":"Bioconjug Chem"},{"key":"383_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neurobiolaging.2014.10.030","volume":"36","author":"M Cortes-Canteli","year":"2015","unstructured":"Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer\u2019s disease brain promotes neuronal degeneration. Neurobiol Aging. 2015;36:608\u201317.","journal-title":"Neurobiol Aging"},{"key":"383_CR6","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.jacc.2019.07.081","volume":"74","author":"M Cortes-Canteli","year":"2019","unstructured":"Cortes-Canteli M, et al. Long-term dabigatran treatment delays Alzheimer\u2019s disease pathogenesis in the TgCRND8 mouse model. J Am Coll Cardiol. 2019;74:1910\u201323.","journal-title":"J Am Coll Cardiol"},{"key":"383_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07358-0","author":"AD Dahl\u00e9n","year":"2025","unstructured":"Dahl\u00e9n AD, et al. PET imaging of TREM2 in amyloid-beta induced neuroinflammation. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07358-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"383_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12987-021-00257-0","volume":"18","author":"R Faresj\u00f6","year":"2021","unstructured":"Faresj\u00f6 R, et al. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. Fluids Barriers CNS. 2021;18:1\u201315.","journal-title":"Fluids Barriers CNS"},{"key":"383_CR3","doi-asserted-by":"crossref","unstructured":"Farkas E, Luiten PGM. Cerebral microvascular pathology in aging and Alzheimer\u2019s disease. Prog Neurobiol. 2001;64 www.elsevier.com\/locate\/pneurobio","DOI":"10.1016\/S0301-0082(00)00068-X"},{"key":"383_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1042\/bj0890114","volume":"89","author":"C Greenwood","year":"1963","unstructured":"Greenwood CBF, Hunter WM, Glover JS. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J. 1963;89:114\u201327.","journal-title":"Biochem J"},{"key":"383_CR8","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.4103\/1673-5374.303029","volume":"16","author":"K Grossmann","year":"2021","unstructured":"Grossmann K. Direct oral anticoagulants: a new therapy against Alzheimer\u2019s disease? Neural Regen Res. 2021;16:1556.","journal-title":"Neural Regen Res"},{"key":"383_CR34","first-page":"57","volume":"122","author":"S Hanaoka","year":"2021","unstructured":"Hanaoka S, Saijou S, Matsumura YA. Novel and potent thrombolytic fusion protein consisting of anti-insoluble fibrin antibody and mutated urokinase. Thromb Haemost. 2021;122:57\u201366.","journal-title":"Thromb Haemost"},{"key":"383_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jpha.2020.07.006","volume":"10","author":"K He","year":"2020","unstructured":"He K, Zeng S, Qian L. Recent progress in the molecular imaging of therapeutic monoclonal antibodies. J Pharm Anal. 2020;10:397\u2013413.","journal-title":"J Pharm Anal"},{"key":"383_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1102\/1470-7330.2006.9098","volume":"6","author":"RJ Hicks","year":"2006","unstructured":"Hicks RJ, Dorow D, Roselt P. PET tracer development\u2013a tale of mice and men. Cancer Imaging. 2006;6:102\u20136.","journal-title":"Cancer Imaging"},{"key":"383_CR2","doi-asserted-by":"publisher","unstructured":"Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204\u20131222 Preprint at https:\/\/doi.org\/10.1016\/j.cell.2012.02.040","DOI":"10.1016\/j.cell.2012.02.040"},{"key":"383_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist G, Syv\u00e4nen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7:308\u201318.","journal-title":"Theranostics"},{"key":"383_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1148\/radiol.2343040197","volume":"234","author":"NA Johnson","year":"2005","unstructured":"Johnson NA, et al. Pattern of cerebral hypoperfusion in alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005;234:851\u20139.","journal-title":"Radiology"},{"key":"383_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines10020305","volume":"10","author":"A Jullienne","year":"2022","unstructured":"Jullienne A, Trinh Mv, Obenaus A. Neuroimaging of mouse models of Alzheimer\u2019s disease. Biomedicines. 2022;10:1\u201335.","journal-title":"Biomedicines"},{"key":"383_CR14","unstructured":"Kristensen JL, Herth MM. In vivo imaging in drug discovery. in Textbook of Drug Design and Discovery 119\u2013135CRC Press, Boca Raton, FL, USA. 2017."},{"key":"383_CR38","doi-asserted-by":"crossref","unstructured":"Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2.","DOI":"10.1162\/15353500200303133"},{"key":"383_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neurobiolaging.2004.12.007","volume":"27","author":"A Lord","year":"2006","unstructured":"Lord A, et al. The Arctic Alzheimer mutation facilitates early intraneuronal A\u03b2 aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27:67\u201377.","journal-title":"Neurobiol Aging"},{"key":"383_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.neuroscience.2005.07.014","volume":"135","author":"Y Ma","year":"2005","unstructured":"Ma Y, et al. A three-dimensional digital atlas database of the adult C57BL\/6J mouse brain by magnetic resonance microscopy. Neuroscience. 2005;135:1203\u201315.","journal-title":"Neuroscience"},{"key":"383_CR32","unstructured":"Matsumura Y, Manabe S, Fuchigami H. Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate. US patent US11311626B2,2020"},{"key":"383_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11307-021-01591-3","volume":"23","author":"SR Meier","year":"2021","unstructured":"Meier SR, Sehlin D, Hultqvist G, Syv\u00e4nen S. Pinpointing brain TREM2 levels in two mouse models of Alzheimer\u2019s disease. Mol Imaging Biol. 2021;23:665\u201375.","journal-title":"Mol Imaging Biol"},{"key":"383_CR24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2967\/jnumed.115.160754","volume":"56","author":"BL Oliveira","year":"2015","unstructured":"Oliveira BL, et al. Multimodal molecular imaging reveals high target uptake and specificity of 111In-and 68Ga-labeled fibrin-binding probes for thrombus detection in rats. J Nucl Med. 2015;56:1587\u201392.","journal-title":"J Nucl Med"},{"key":"383_CR35","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.neurobiolaging.2007.11.022","volume":"30","author":"O Philipson","year":"2009","unstructured":"Philipson O, et al. A highly insoluble state of A\u03b2 similar to that of Alzheimer\u2019s disease brain is found in Arctic APP transgenic mice. Neurobiol Aging. 2009;30:1393\u2013405.","journal-title":"Neurobiol Aging"},{"key":"383_CR11","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1021\/jm5001858","volume":"57","author":"M Piel","year":"2014","unstructured":"Piel M, Vernaleken I, R\u00f6sch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. 2014;57:9232\u201358.","journal-title":"J Med Chem"},{"key":"383_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/07357907.2018.1430816","volume":"36","author":"D Psimadas","year":"2018","unstructured":"Psimadas D, Valotassiou V, Alexiou S, Tsougos I, Georgoulias P. Radiolabeled mAbs as molecular imaging and\/or therapy agents targeting PSMA. Cancer Invest. 2018;36:118\u201328.","journal-title":"Cancer Invest"},{"key":"383_CR31","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41590-018-0232-x","volume":"19","author":"JK Ryu","year":"2018","unstructured":"Ryu JK, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol. 2018;19:1212\u201323.","journal-title":"Nat Immunol"},{"key":"383_CR18","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1038\/ncomms10759","volume":"7","author":"D Sehlin","year":"2016","unstructured":"Sehlin D, et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease. Nat Commun. 2016;7:10759.","journal-title":"Nat Commun"},{"key":"383_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17358-2","volume":"7","author":"D Sehlin","year":"2017","unstructured":"Sehlin D, Fang XT, Meier SR, Jansson M, Syv\u00e4nen S. Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-\u03b2. Sci Rep. 2017;7:1\u20139.","journal-title":"Sci Rep"},{"key":"383_CR22","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1007\/s00259-019-04426-0","volume":"46","author":"D Sehlin","year":"2019","unstructured":"Sehlin D, et al. Engineered antibodies: new possibilities for brain PET? Eur J Nucl Med Mol Imaging. 2019;46:2848\u201358.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"383_CR19","doi-asserted-by":"publisher","unstructured":"Sehlin D, et al. Bispecific brain-penetrant antibodies for treatment of Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2025;100214. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100214","DOI":"10.1016\/j.tjpad.2025.100214"},{"key":"383_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00259-008-1028-2","volume":"36","author":"W Staffen","year":"2009","unstructured":"Staffen W, et al. Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer\u2019s type: a semiquantitative and automated evaluation. Eur J Nucl Med Mol Imaging. 2009;36:801\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"383_CR7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bph.16032","volume":"181","author":"R Toribio-Fernandez","year":"2024","unstructured":"Toribio-Fernandez R, et al. Oral anticoagulants: a plausible new treatment for Alzheimer\u2019s disease? Br J Pharmacol. 2024;181:760\u201376.","journal-title":"Br J Pharmacol"},{"key":"383_CR25","doi-asserted-by":"crossref","unstructured":"van den Lopes S et al. Pretargeted imaging beyond the blood\u2013brain barrier\u2014utopia or feasible? Pharmaceuticals. 2022;15:1\u201315.","DOI":"10.3390\/ph15101191"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00383-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:06:15Z","timestamp":1757498775000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00383-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00383-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.06.02.657356","asserted-by":"object"}]},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were conducted under ethical permit number 5.8.18\u201320401\/2020, issued by the Uppsala County Animal Ethics board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests\n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}